Elacestrant and Trastuzumab Deruxtecan Approvals Prompt Sequencing Considerations in HR+ Breast Cancer
Manali Bhave, MD, discusses the effect of emerging therapies on the treatment landscape for patients with HR-positive, HER2-negative or -low breast cancer, highlighted her stance on sequencing decisions for these patients, and expanded on the additional work being done to optimize treatment sequencing from a growing list of options.
Source: onclive.com
